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ABSTRACT
Drug-induced cardiotoxicity usually manifests as heart failure or left ventricular systolic dysfunction.
Left ventricular dysfunction is a rarely reported side effect of bevacizumab (BEV) with an incidence of
1.2%, and this occurs irrespective of the route of administration. In this study, we focused on an ana-
lysis of BEV effects on mitochondrial complexes activities and protective effect of ellagic acid (EA)
against BEV-induced mitochondria toxicity. Rat heart mitochondria were isolated using differential cen-
trifugation form wistar rats. Using biochemical and flowcytometry assays we evaluated mitochondrial
complexes activity, succinate dehydrogenases (SDH), mitochondrial swelling, reactive oxygen species
(ROS) formation and mitochondrial membrane potential (MMP) in isolated mitochondria. We observed
only decreased activity of complexes II after exposure with BEV (50 and 100 mg/ml). The inhibition of
complex II is paralleled by the decreased MMP, mitochondrial swelling, and ROS formation. Also, we
showed that EA (10–100 mM) as an antioxidant and natural agent significantly decreases mitochondrial
toxicity induced by BEV. Together, for the first time, this preliminary study has demonstrated a signifi-
cant decrease in activity of complexes II after exposure with BEV and proved the protective effects of
EA in alleviating BEV-mediated mitochondria toxicity.
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Introduction
As cancer treatments continue to progress and improve, the
adverse cardiovascular side effects events related to cancer
treatment have also attracted more attention (Curigliano
et al. 2016). Antiangiogenic drugs such as bevacizumab (BEV)
that have been approved for the treatment of several cancers
inhibit hypoxia-inducible factor 1-related signaling and vascu-
lar endothelial growth factor (VEGF) (Kerbel 2006). Several
adverse cardiovascular effects like left ventricular dysfunction
and subsequent heart failure have been reported in the pre-
vious studies (Schmidinger et al. 2007). Antiangiogenic drugs
develop myocardial dysfunction probably on the basis of the
heart’s dependence on adequate angiogenesis and mito-
chondria-related signaling pathways (Chu et al. 2007). BEV as
a recombinant humanized monoclonal antibody shows
approximately 2% of development of cardiomyopathy and
heart failure in BEV-treated patients (Bordun et al. 2015).
Large molecules BEV as monoclonal antibody can be internal-
ized through the nonselective process such as macropinocy-
tosis and selective process related to Fc receptor (FcRn) (Lim
and Gleeson 2011). Macropinocytosis process is originated
from actin-containing plasma membrane extensions, resulting
in large endocytic vacuoles called macropinosomes that
ultimately become early endosomes (Commisso et al. 2013).
A recent study on glioblastoma (GBM) cells showed that BEV
is internalized rapidly through macropinocytosis into cells
and is detected in the lysosomes (M€uller-Greven et al. 2017).
Also, the same internalization and accumulation of BEV were
shown in retinal endothelial cells accompanied by interaction
with the cytoskeleton (Deissler et al. 2016). Their studies sug-
gest that BEV can internalize into cell from different process.
Therefore, chances of exposure of mitochondria to BEV in
cardiomyocytes are possible.
Although cardiovascular safety concerns of many widely
used drugs like BEV have been identified today, the cellular
mechanisms of adverse cardiac effects are poorly understood.
As well as, the predictive value of now existing toxicity
screening methods is very poor, especially in individuals with
cardiovascular abnormalities (Madonna et al. 2015).
Notwithstanding the great attempts to disclose cardiotoxicity
in the preclinical phase and clinical trials of development of
drugs, cardiotoxicity continues to lead safety concerns. This is
clearly owing to the lack of enough knowledge of the mech-
anisms of cardiotoxicity (Kang 2001). New evidence proposes
that cardiotoxicity of drugs usually induce mitochondrial dys-
function (Varga et al. 2015). There are adequate reasons to
evaluate the role of drugs in inducing mitochondrial impair-
ments and the leading potential toxic effects or mitochon-
drial dysfunction. Knowledge of these mechanistic studies on
mitochondrial may help the clinicians design safer thera-
peutic regimens in the patients (Pereira et al. 2009). In add-
ition, a published work indicated that the predictive
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performance of the mitochondrial assays for cardiotoxicity is
33% (Rana et al. 2019).
Numerous studies showed the beneficial effects of natural
products against cardiotoxicity. Regardless of sources of anti-
oxidants natural products are known to prevent the progres-
sion of cardiac tissue damage (Yu et al. 2018). Ellagic acid
(EA), a type of natural compound, is widely distributed in
plants and has been demonstrated to possess a strong ability
to scavenge free radicals. EA has shown anti-apoptosis and
anti-inflammatory activities in many systems. Many studies
have reported that EA has strong antioxidant activities
(Salimi et al. 2015, Chen et al. 2018). To our knowledge, there
are no reports to date about the effect of BEV on mitochon-
drial complexes and protective effect of EA on BEV-induced
mitochondria dysfunction in isolated mitochondria as promis-
ing system for perdition of cardiotoxicity. Thus, this study
aims to search the effect of BEV on mitochondrial complexes
and protective effect of EA on BEV-induced mitochon-
dria toxicity.
Material and methods
Animals
Male wistar rats (8–9 weeks old) weighting 200–300 g were
purchased from the Pasteur Institute of Iran (Tehran, Iran).
Animals were housed under standard conditions (tempera-
ture 22–21 C, humidity 50–10%, 12 h light–dark cycle and
free access to food and water). This study was approved by
the Ethics Committee at the Ardabil University of Medical
Sciences with ethics code IR.ARUMS.REC.1397.275, and per-
formed strictly in accordance with institutional and inter-
national guide for animal care.
Chemicals
Rhodamine123, 20,70-dichlorofluorescin diacetate (DCFH-DA),
N-(2-hydroxyethyl) pi-perazine-N0-(2-ethanesulfonic acid)
(HEPES), trypan blue, ethylene glycol-bis(b-aminoethyl ether
(EGTA), bovine serum albumin (BSA), coomassie brilliant blue,
2,20,200,2000-(ethane-1,2-diyldinitrilo)tetraacetic acid (EDTA),
sucrose, D-mannitol, dimethyl sulfoxide (DMSO), 2-amino-2-
hydroxymethyl-propane-1,3-diol (TRIS), 3-4,5-dimethylthiazol-
2-yl)-2,5-diphenyltetrazolium bromide (MTT), monopotassium
phosphate, 3-morpholinopropane-1-sulfonic acid (MOPS),
sodium succinate, rotenone, magnesium chloride, and
potassium chloride were purchased from Sigma (St. Louis,
MO) (Cambridge, UK).
Preparation of mitochondria
Rats were decapitated and the heart was surgically extracted.
The isolated heart was chopped, cleared from blood vessels,
and destroyed with a glass homogenizer in a 10-fold volume
of the medium containing 225mM D-mannitol, 75mM
sucrose, and 0.2mM EDTA, pH 7.4 in ice-cold bath. The hom-
ogenate was centrifuged at 1000g for 10min, and the pel-
let was removed. The mitochondria contained in the
supernatant were sedimented at 10 000 g for 10min at
4 C (Odinokova et al. 2018). The protein content in mito-
chondria was determined using the Bradford assay was deter-
mined (Bradford 1976). Protein concentration in the
suspension was 1mg/ml.
Spectrophotometric measurement of enzyme activity
The enzymatic activities of oxidative phosphorylation
(OXPHOS) complexes I, II, III, IV, Iþ III, IIþ III, and citrate syn-
thase were measured in isolated rat heart intact mitochondria
according to presented situation in Table 1 (Spinazzi et al.
2012). For all assays, enzymatic activity was measured in the
presence of 50 and 100 mg/ml BEV for 30min. Experiments
were performed at least three times for each treatment.
Significant differences between control and treated samples
were determined using one-way ANOVA test (Spinazzi
et al. 2012).
Measurement of NADH/succinate dehydrogenase activity
The activity of NADH dehydrogenase (complex I) and/or suc-
cinate dehydrogenase (complex II), was assayed by using
MTT reduction (Hosseini et al. 2013). Briefly, after incubation
of mitochondrial suspensions with BEV (50 and 100 mg/ml)
and EA (10, 50, and 100 mM) at 37 C for 60min and then
was added 0.4% MTT to the medium, samples were incu-
bated at 37 C for 30min. Then, the purple formazan crystals
were dissolved in DMSO and the absorbance was measured
at 570 nm with an ELISA reader (BioTek, Winooski, VT) (Liu
et al. 1997).
Table 1. Conditions for spectrophotometric assays of respiratory chain enzymes activity in isolated rat heart mitochondria.
Complex I Complex II Complex III Complex IV Complex Iþ III Complex IIþ III
k (nm) 340 600 550 550 550 550
Buffer KP KP KP KP KP KP
pH 7.5 7.5 7.5 7 7.5 7.5
Substrates/
electron
acceptors
NADH, 100 mM Ub
1, 60 mM
Succinate, 20mM
DCPIP, 80 mM
DUB 50 mM
DubH 2, 100 mM Cyt
c, 75 mM
Cyt c H2, 60 mM NADH, 200 mM Cyt
c, 50 mM
Succinate, 10mM
Cyt c, 50 mM
Detergent – – Tween-20 (0.025%,
vol/vol)
– – –
Specific inhibitor Rotenone, 10 mM Malonate, 10mM Antimycin A,
10 mg ml1
KCN, 300 mM Rotenone, 10 mM Malonate, 10mM
k: selected wavelength for the assay; Cyt c: cytochrome c; Cyt c H2: reduced cytochrome c; DCPIP: 2,6-dichlorophenolindophenol; DUB: decylubiquinone; DubH2:
decylubiquinol; DTNB: 5,50-dithiobis (2-nitrobenzoic acid); KCN: potassium cyanide; KP: potassium phosphate buffer; Ub1: ubiquinone1.
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Quantification of mitochondrial ROS formation
After incubation of isolated heart mitochondria with BEV (50
and 100 mg/ml) and EA (10, 50, and 100 mM) in respiration
buffer (0.32mM sucrose, 10mM Tris, 20mM Mops, 50 lM
EGTA, 0.5mM MgCl2, 0.1mM KH2PO4, 5mM sodium succin-
ate, and 10 mM DCFH-DA). The mitochondrial H2O2 produc-
tion was assayed by flowcytometry (Cyflow Space-Partec,
Germany) in the period of 60min. Mitochondria were read
on the FL1 channel of flowcytometry and mean of fluores-
cence intensities were compared between groups (Eruslanov
and Kusmartsev 2010).
Determination of MMP collapse
Rhodamine 123 as cationic fluorescent dye has been used for
the determination of MMP collapse. Briefly, mitochondria
were suspended in MMP buffer including 220mM sucrose,
68mM D-mannitol, 10mM KCl, 5mM KH2PO4, 2mM MgCl2,
50lM EGTA, 5mM sodium succinate, 10mM HEPES, 2lM
Rotenone, and 10 mM of rhodamine123. Then mitochondria
were incubated with BEV (50 and 100 mg/ml) and EA (10, 50,
and 100 mM) at 37 C for 5min. The fluorescence was meas-
ured using flowcytometry (Cyflow Space-Partec, Germany).
Mitochondria were read on the FL1 channel of flowcytometry
and mean of fluorescence intensities were compared
between groups (O’Connor et al. 1988).
Determination of mitochondrial swelling
The change in mitochondrial volume, due to the colloidal
osmotic effects of solute flux into and out of the mitochon-
drial matrix was measured by monitoring the absorbance at
540 nm (A540). Briefly, after incubation of mitochondrial sus-
pensions with BEV (50 and 100 mg/ml) and EA (10, 50, and
100 mM) at 37 C for 5min in swelling buffer (70mM sucrose,
230mM mannitol, 3mM HEPES, 2mM Tris-phosphate, 5mM
succinate, and 1 mM of rotenone), the absorbance was meas-
ured at 540 nm at 60min with an ELISA reader (BioTek,
Winooski, VT, USA). A decrease in the absorbance indicates
an increase in mitochondrial swelling (Gerencser et al. 2008).
Statistical analysis
The results were analyzed using Graph Pad Prism version 5
(Graph Pad Software Inc., La Jolla, CA). Results are presented
as mean± SD. Assays were performed in triplicate and the
mean was used for statistical analysis. Statistical significance
was determined using the one-way ANOVA test, followed by
the post-hoc Tukey posttest and two-way ANOVA followed by
the posttest Bonferonie. Statistical significance was set at
p< 0.05. Also, the flow cytometric data was obtained with
Cyflow Space-Partec and analyzed by FlowJo.
Results
OXPHOS enzymatic activity
OXPHOS enzymatic activity in isolated mitochondria obtained
from rat heart was measured. Complex II activity was signifi-
cantly reduced by BEV at 50 and 100 mg/ml compared with
control group (Figure 1(B)). Activities of complexes I, III, and
IV were not affected by BEV (Figure 1(A,C,D)). Also complexes
I/III and II/III activity were not significantly reduced to control
activity by BEV (Figure 1(E,F)). In summary, these results
Figure 1. OXPHOS enzyme activities of complex I (A), complex II (B), complex III (C), complex IV (D), complex Iþ III (E) and complex IIþ III (F) in isolated rat heart
intact mitochondria. Only complex II activity was significantly reduced by bevacizumab at 50 and 100 mg/ml compared with control group but not in other
complexes. and indicate p< 0.01 and p< 0.001 vs. control respectively. Three independent experiments were run for each complex.
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confirm that complex II is the principal OXPHOS target for
BEV in rat heart mitochondria.
Measurement of NADH/succinate dehydrogenase activity
Evaluations of BEV for potential activity on mitochondria
obtained from rat heart mitochondria were carried out by
studying the inhibitory effects of this drug on NADH/succin-
ate dehydrogenase activity using the MTT assay. BEV (up to
50 mg/ml) inhibited succinate dehydrogenase activity after
1 h of exposure (Figure 2). The presented data at Figure 2
demonstrated that EA (10, 50, and 100 mg/ml) prevent mito-
chondria toxicity induced by BEV.
ROS formation assay
Reactive oxygen species (ROS) plays a key role in cell survival
and death. We evaluated the effect of BEV on ROS formation
in isolated rat heart mitochondria using DCFH-DA staining.
As shown in Figure 3, treatment with BEV at up to 50 mg/ml
at 1 h, significantly (p< 0.05) induced ROS generation in iso-
lated rat heart mitochondria. These results suggested that
BEV induced ROS generation might antioxidant agents such
as EA inhibits the ROS formation induced by this drug. When
the isolated mitochondria were simultaneously treated with
BEVþ EA, the mean fluorescence intensities were significantly
decreased compared to treated groups with BEV (Figure 3).
Mitochondrial swelling
Induction of mitochondrial swelling in isolated mitochondria
was monitored by following 540 nm absorbance (A540)
decrease. BEV (up to 50 mg/ml for 1 h) resulted in an exten-
sive mitochondrial swelling in isolated rat heart mitochondria
(Figure 4). Also, our result showed that mitochondrial swel-
ling was inhibited after treatment of isolated mitochondria
with BEV at toxic doses by EA (10, 50, and 100 mg/ml).
MMP collapse
To search for the identification of mechanisms involved in
apoptosis, we examined the effects of BEV on membrane
permeability of mitochondria (DWm) in isolated rat heart
mitochondria. Treatment with of BEV (up to 50 mg/ml for 1 h)
induced significant decrease in DWm (Figure 5) in isolated rat
heart mitochondria. As shown in Figure 5, collapse of mito-
chondrial membrane potential (MMP) was inhibited after
treatment of mitochondria with BEV by EA (10, 50, and
100 mg/ml).
Discussion
Depending on the reversibility of myocardial damage, there
are two types anticancer drug-induced cardiotoxicity. Type I
anticancer drugs such as anthracyclines, alkylating agents,
and antimicrotubule agents directly cause cell death resulting
in irreversible myocyte destruction and congestive heart fail-
ure or CHF. On the other hand, type II cardiotoxic anticancer
drugs change normal cellular function by affecting the pro-
tein synthesis and the mitochondrial system (Jain et al. 2017).
Type II cardiotoxicity was first described with VEGF inhibitors
and tyrosine kinase inhibitors like trastuzumab
(Economopoulou et al. 2015). Endothelial growth factor inhib-
itors disrupt the VEGF signaling cascade and induce cardio-
vascular toxicity. VEGF is a modulator of growth and
myocardial function. Therefore, VEGF inhibitors may produce
different forms of cardiovascular toxicity, mainly left ventricu-
lar dysfunction, thromboembolism (TE), heart failure, and
hypertension (Touyz and Herrmann 2018). In mitochondria,
VEGF signaling pathway stimulates the angiogenesis by pro-
moting the mitochondrial functions including mitochondrial
oxidative respiration, intracellular ATP levels, ROS production
decrease, and increase in the enzymes of ROS defense sys-
tem, including catalase and glutathione peroxidase (GPX1)
(Guo et al. 2017). Also, VEGF activated mammalian target of
rapamycinm (mTOR) signaling pathway to promote the func-
tion of mitochondria (Laplante and Sabatini 2012). Therefore,
VEGF inhibitors could decrease mitochondrial activity and
impair cardiomyocyte function. The myocardium requires
appropriate perfusion to function properly and it depends on
VEGF and HIF-1 pathways, similar to tumors. Therefore, inhib-
ition of a VEGF may cause microvessel rarefaction and myo-
cardial hibernation, which can be reversed by elimination of
the VEGF inhibitor (Ramakrishnan et al. 2014). Such depend-
ency shows that the myocardium is very sensitive to anti-
angiogenic treatments, like BEV (Ramakrishnan et al. 2014).
BEV as an VEGF inhibitor, is now widely used for the
Figure 2. Effect of bevacizumab on succinate dehydrogenase activity and pro-
tective effect of EA in isolated rat heart mitochondria. Mitochondrial succinate
dehydrogenase activity was measured by MTT assay within 1 h. Presented data
showed bevacizumab significantly decreased succinate dehydrogenase activity
compared to control. Also, protective effect of EA is tested against mitochon-
drial toxicity induced bevacizumab. This data showed EA significantly increased
succinate dehydrogenase activity compared to treated groups with bevacizu-
mab alone. Values were expressed as mean ± SD of three separate determina-
tions. indicates p< 0.001 vs. control and ###indicates p< 0.001 vs. treated
group with bevacizumab.
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treatment of several cancers. Previous study showed that BEV
as a mitochondrial membrane depolarizer had a direct per-
turbation effect in the mitochondria of primary brain tumors
(Nanegrungsunk et al. 2016). They showed that BEV -induced
mitochondrial depolarization is independent from the ROS
pathway since the application of BEV to brain tumor mito-
chondria did not increase ROS formation (Nanegrungsunk
et al. 2016). They suggested that probably BEV could directly
open the mitochondrial permeability transition pore (mPTP
or MPTP), subsequently depolarize the mitochondrial mem-
brane and cause mitochondrial swelling (Nanegrungsunk
et al. 2016). Moreover, BEV exposure for 5 d was safe at clin-
ical doses in both human retinal pigment epithelial (ARPE-19)
and rat neurosensory retinal (R28) cells in culture (Luthra
et al. 2013). By contrast, BEV exposure at all doses shows a
significant dose-dependent decrease in mitochondrial activity
in both the proliferating and non-proliferating human micro-
vascular endothelial (HMVEC) in vitro (Luthra et al. 2013).
Obtained results suggest a selective action of BEV on endo-
thelial cells at clinical doses (Luthra et al. 2013). Our result for
first time proved that BEV has a direct perturbation effect in
isolated rat heart mitochondria and causes mitochondrial oxi-
dative stress, permeabilizing the mitochondrial membrane
and mitochondrial swelling as the ‘point of no return’ in the
cascade of events leading to cell death.
In many cases, cardiotoxicity problems emerge only in the
presence of additional cardiovascular disease conditions or
appear months/years following the exposure (Varga et al.
2015). Heart isolated mitochondria as a good tool could
be more effective in prediction of cardiotoxic agents.
Figure 4. Effect of bevacizumab on mitochondrial swelling and protective effect
of EA in isolated rat heart mitochondria. Mitochondrial swelling was monitored
by following 540 nm absorbance decrease. Bevacizumab at concentration
50 mg/ml induced mitochondrial swelling in in isolated rat heart mitochondria
in a time depending manner. EA significantly inhibited mitochondrial swelling
compared to treated groups with bevacizumab alone. Values were expressed as
mean ± SD of three separate determinations. indicates p< 0.001 vs. control
and ###indicates p< 0.001 vs. treated group with bevacizumab.
Figure 3. Effect of bevacizumab on ROS formation and protective effect of EA in isolated rat heart mitochondria. Changes in ROS generation were measured in iso-
lated mitochondria after treatment with bevacizumab (50 mg/ml) for 1 h. The fluorescence intensity of DCF was significantly (p< 0.05) increased in bevacizumab-
treated mitochondria. Also, protective effect of EA is tested against ROS formation induced bevacizumab. This data showed EA significantly decreased ROS formation
compared to treated groups with bevacizumab alone. Values were expressed as mean ± SD of three separate determinations. indicates p< 0.001 vs. control and
###indicates p< 0.001 vs. treated group with bevacizumab.
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In mitochondria, cardiotoxic drugs induce toxicity through
different mechanism of actions such as interference with the
mitochondrial respiratory chain and/or inhibition of the
important mitochondrial enzymes (Varga et al. 2015, Gorini
et al. 2018). The final phase of mitochondrial dysfunction
induces an increase in mitochondrial oxidative stress and loss
of MMP, eventually lead to cell death (Varga et al. 2015,
Kuznetsov et al. 2011). Our results on isolated mitochondria
showed that BEV inhibits mitochondrial complex 2 and prob-
ably triggers other mitochondrial toxicity events. The majority
of ROS is produced as a by-product of mitochondrial respir-
ation and about 2% of the molecular oxygen is converted
into superoxide radicals by mitochondria in normal cells
(Zorov et al. 2014). Main sites of superoxide generation by
mitochondria are complexes I and III (Zhao et al. 2019).
Besides complexes I and III, succinate dehydrogenase com-
plex (complex II) is also considered to be an important site of
excessive superoxide formation, particularly when mitochon-
drial respiration is suppressed and there is an excess of suc-
cinate levels (Scialo et al. 2017). In these situations, reverse
electron transport occurs to complex I, resulting in extensive
uncontrolled ROS formation and the accumulated succinate
is quickly reoxidized by complex II, leading to further ROS
production (Scialo et al. 2017).
Cardiotoxicity induced by drugs and chemicals is closely
linked to mitochondrial oxidative stress (Deavall et al. 2012).
This situation resulted in oxidative stress from the imbalance
generation of ROS and antioxidant defense systems. Thereby,
oxidative stress contributes to cardiovascular complications
and endothelial dysfunction (Incalza et al. 2018). Natural
products have appeared as a potential source of bioactive
compounds which have shown to protect against cardiotoxic-
ity-induced by oxidative stress (Ooi et al. 2018, Arbelaez et al.
2018). There are many works showed that EA, as a phenolic
compound has cardioprotective effect against chemical and
drug-induced cardiotoxicity (Warpe et al. 2015, Hemmati
et al. 2018). In this study, we proved that EA has mitochon-
drial protective effect against toxicity induced by BEV, which
is consistent with previously published data examining anti-
oxidant and cardioprotective effects of EA in several systems.
A published study suggests that protective effect of EA may
be accomplished particularly throughout the mitochondrial
maintenance either directly by its antioxidant property or
indirectly through its maintaining of complex II (Keshtzar
et al. 2016). These findings also suggest a potential role for
EA in treating or preventing mitochondria associated disor-
ders. In summary, BEV directly induced mitochondrial dys-
function in rat heart mitochondria due to, its ability to
induce ROS production through complex II inhibition which
lead to permeabilizing the mitochondrial membrane and
mitochondrial swelling. Finally, this study suggests a possible
usefulness of EA as a mitochondrial protective agent contri-
buting to a safer use of BEV in patient subjected to
chemotherapy.
Figure 5. Effect of bevacizumab on DWm and protective effect of EA in isolated rat heart mitochondria. Freshly isolated mitochondria were incubated with
50 mg/ml bevacizumab for 1 h. DWm was measured following rhodamine 123 staining with flow cytometry. The presented data revealed that exposure to bevacizu-
mab caused a significant increase in the fluorescence intensity of rhodamine 123 and it reflects MMP collapse. In addition to this figure shows EA prevented bevaci-
zumab-induced MMP collapse. indicates p< 0.001 vs. control and ###indicates p< 0.001 vs. treated group with bevacizumab.
6 E. M. KHANLOU ET AL.
Acknowledgments
The data provided in this article was extracted from the Pharm D. thesis
of Dr. Elham Mohammad Khanlou. The thesis was conducted under
supervision of Dr. Ahmad Salimi at Department of Pharmacology and
Toxicology, School of Pharmacy, Ardabil University of Medical Sciences,
Ardabil, Iran. This study was supported by Ardabil University of Medical
Sciences, Deputy of Research with ethics code IR.ARUMS.REC.1397.275.
Disclosure statement
The authors declare that they have no conflict of interest.
References
Arbelaez, L.F.G., et al., 2018. Cardioprotection and natural polyphenols:
an update of clinical and experimental studies. Food & Function, 9,
6129–6145.
Bordun, K.A., et al., 2015. The utility of cardiac biomarkers and echocardi-
ography for the early detection of bevacizumab-and sunitinib-medi-
ated cardiotoxicity. American Journal of Physiology-Heart and
Circulatory Physiology, 309 (4), H692–H701.
Bradford, M.M., 1976. A rapid and sensitive method for the quantitation
of microgram quantities of protein utilizing the principle of protein-
dye binding. Analytical Biochemistry, 72 (1–2), 248–254.
Chen, P., Chen, F., and Zhou, B., 2018. Antioxidative, anti-inflammatory
and anti-apoptotic effects of ellagic acid in liver and brain of rats
treated by D-galactose. Scientific Reports, 8 (1), 1465.
Chu, T.F., et al., 2007. Cardiotoxicity associated with tyrosine kinase
inhibitor sunitinib. The Lancet, 370 (9604), 2011–2019.
Commisso, C., et al., 2013. Macropinocytosis of protein is an amino acid
supply route in Ras-transformed cells. Nature, 497 (7451), 633–637.
Curigliano, G., et al., 2016. Cardiotoxicity of anticancer treatments: epi-
demiology, detection, and management. CA: A Cancer Journal for
Clinicians, 66, 309–325.
Deavall, D.G., et al., 2012. Drug-induced oxidative stress and toxicity.
Journal of Toxicology, 2012, 1–13.
Deissler, H.L., Lang, G.K., and Lang, G.E., 2016. Internalization of bevacizu-
mab by retinal endothelial cells and its intracellular fate: evidence for
an involvement of the neonatal Fc receptor. Experimental Eye
Research, 143, 49–59.
Economopoulou, P., et al., 2015. Cancer therapy and cardiovascular risk:
focus on bevacizumab. Cancer Management and Research, 7, 133–143.
Eruslanov, E. and Kusmartsev, S., 2010. Identification of ROS using oxi-
dized DCFDA and flow-cytometry. In: D. Armstrong, ed. Advanced pro-
tocols in oxidative stress II. Totowa, NJ: Humana Press, 57–72.
Gerencser, A.A., et al., 2008. Mitochondrial swelling measurement in situ
by optimized spatial filtering: astrocyte-neuron differences. Biophysical
Journal, 95 (5), 2583–2598.
Gorini, S., et al., 2018. Chemotherapeutic drugs and mitochondrial dys-
function: focus on doxorubicin, trastuzumab, and sunitinib. Oxidative
Medicine and Cellular Longevity, 2018, 1–15.
Guo, D., et al., 2017. VEGF stimulated the angiogenesis by promoting the
mitochondrial functions. Oncotarget, 8, 77020.
Hemmati, A., et al., 2018. Ellagic acid protects against arsenic trioxide–in-
duced cardiotoxicity in rat. Human & Experimental Toxicology, 37,
412–419.
Hosseini, M.J., et al., 2013. Toxicity of cigarette smoke on isolated lung,
heart, and brain mitochondria: induction of oxidative stress and cyto-
chrome c release. Toxicological & Environmental Chemistry, 95,
1624–1637.
Incalza, M.A., et al., 2018. Oxidative stress and reactive oxygen species in
endothelial dysfunction associated with cardiovascular and metabolic
diseases. Vascular Pharmacology, 100, 1–19.
Jain, D., et al., 2017. Cardiotoxicity of cancer chemotherapy: identification,
prevention and treatment. Annals of Translational Medicine, 5 (17),
348–348.
Kang, Y.J., 2001. Molecular and cellular mechanisms of cardiotoxicity.
Environmental Health Perspectives, 109, 27–34.
Kerbel, R.S., 2006. Antiangiogenic therapy: a universal chemosensitization
strategy for cancer? Science, 312 (5777), 1171–1175.
Keshtzar, E., et al., 2016. Ellagic acid protects against arsenic toxicity in
isolated rat mitochondria possibly through the maintaining of com-
plex II. Human & Experimental Toxicology, 35, 1060–1072.
Kuznetsov, A.V., et al., 2011. Changes in mitochondrial redox state, mem-
brane potential and calcium precede mitochondrial dysfunction in
doxorubicin-induced cell death. Biochimica et Biophysica Acta (Bba) -
Molecular Cell Research, 1813 (6), 1144–1152.
Laplante, M. and Sabatini, D.M., 2012. mTOR signaling in growth control
and disease. Cell, 149 (2), 274–293.
Lim, J.P. and Gleeson, P.A., 2011. Macropinocytosis: an endocytic pathway
for internalising large gulps. Immunology and Cell Biology, 89 (8),
836–843.
Liu, Y., et al., 1997. Mechanism of cellular 3-(4, 5-dimethylthiazol-2-yl)-2,
5-diphenyltetrazolium bromide (MTT) reduction. Journal of
Neurochemistry, 69 (2), 581–593.
Luthra, S., et al., 2013. Effect of bevacizumab (AvastinTM) on mitochon-
drial function of in vitro retinal pigment epithelial, neurosensory ret-
inal and microvascular endothelial cells. Indian Journal of
Ophthalmology, 61, 705.
Madonna, R., et al., 2015. Improving the preclinical models for the study
of chemotherapy-induced cardiotoxicity: a Position Paper of the
Italian Working Group on Drug Cardiotoxicity and Cardioprotection.
Heart Failure Reviews, 20 (5), 621–631.
M€uller-Greven, G., et al., 2017. Macropinocytosis of Bevacizumab by
Glioblastoma cells in the perivascular niche affects their survival.
Clinical Cancer Research, 23 (22), 7059–7071.
Nanegrungsunk, D., et al., 2016. Bevacizumab is superior to
Temozolomide in causing mitochondrial dysfunction in human brain
tumors. Neurological Research, 38 (4), 285–293.
O’Connor, J.E., et al., 1988. Use of rhodamine 123 to investigate altera-
tions in mitochondrial activity in isolated mouse liver mitochondria.
Biochemical and Biophysical Research Communications, 151, 568–573.
Odinokova, I., et al., 2018. Effect of melatonin on rat heart mitochondria
in acute heart failure in aged rats. International Journal of Molecular
Sciences, 19 (6), 1555.
Ooi, B.K., et al., 2018. The role of natural products in targeting cardiovas-
cular diseases via Nrf2 pathway: novel molecular mechanisms and
therapeutic approaches. Frontiers in Pharmacology, 9, 1308.
Pereira, C.V., et al., 2009. Investigating drug-induced mitochondrial tox-
icity: a biosensor to increase drug safety? Current Drug Safety, 4 (1),
34–54.
Ramakrishnan, S., Anand, V., and Roy, S., 2014. Vascular endothelial
growth factor signaling in hypoxia and inflammation. Journal of
Neuroimmune Pharmacology, 9 (2), 142–160.
Rana, P., et al., 2019. Evaluation of in vitro mitochondrial toxicity assays
and physicochemical properties for prediction of organ toxicity using
228 pharmaceutical drugs. Chemical Research in Toxicology, 32 (1),
156–167.
Salimi, A., et al., 2015. Ellagic acid, a polyphenolic compound, selectively
induces ROS-mediated apoptosis in cancerous B-lymphocytes of CLL
patients by directly targeting mitochondria. Redox Biology, 6, 461–471.
Schmidinger, M., et al., 2007. Cardiac toxicity of sunitinib and sorafenib
in patients with metastatic renal cell carcinoma. Journal of Clinical
Oncology, 26, 5204–5212.
Scialo, F., Fernandez-Ayala, D.J., and Sanz, A., 2017. Role of mitochondrial
reverse electron transport in ROS signaling: potential roles in health
and disease. Frontiers in Physiology, 8, 428.
Spinazzi, M., et al., 2012. Assessment of mitochondrial respiratory chain
enzymatic activities on tissues and cultured cells. Nature Protocols, 7
(6), 1235–1246.
Touyz, R.M. and Herrmann, J., 2018. Cardiotoxicity with vascular endothe-
lial growth factor inhibitor therapy. NPJ Precision Oncology, 2 (1), 13.
Varga, Z.V., et al., 2015. Drug-induced mitochondrial dysfunction and car-
diotoxicity. American Journal of Physiology-Heart and Circulatory
Physiology, 309 (9), H1453–H1467.
DRUG AND CHEMICAL TOXICOLOGY 7
Warpe, V.S., et al., 2015. Cardioprotective effect of ellagic acid on doxo-
rubicin induced cardiotoxicity in wistar rats. Journal of Acute Medicine,
5 (1), 1–8.
Yu, J., et al., 2018. Recent progress in doxorubicin-induced cardiotoxicity
and protective potential of natural products. Phytomedicine, 40,
125–139.
Zhao, R.Z., et al., 2019. Mitochondrial electron transport chain, ROS gen-
eration and uncoupling. International Journal of Molecular Medicine,
44, 3–15.
Zorov, D.B., Juhaszova, M., and Sollott, S.J., 2014. Mitochondrial reactive
oxygen species (ROS) and ROS-induced ROS release. Physiological
Reviews, 94 (3), 909–950.
8 E. M. KHANLOU ET AL.
